12th Aug 2025 13:18
(Alliance News) - PureTech Health PLC on Tuesday said it is launching a subsidiary focused on drugs to treat respiratory diseases.
The Boston, Massachusetts-based biotech and pharmaceutical firm has named the new business Celea Therapeutics. Its lead drug candidate is deupirfenidone or LYT-100, which targets lung conditions.
According to PureTech, LYT-100 "holds promise across multiple fibrotic and inflammatory lung conditions", though its initial focus is idiopathic pulmonary fibrosis, a fatal form of tissue scarring.
PureTech has promoted Sven Dethlefs, who has been involved in the drug's development over the past year, to lead Celea. Dethlefs is the ex-chief executive of North America at Teva Pharmaceuticals Industries Ltd and a former partner at McKinsey & Co.
"I believe deupirfenidone has the potential to be a true turning point in the treatment of IPF," Dethlefs said.
"The strength of the clinical data, combined with the team and mission behind Celea, make this a uniquely compelling opportunity."
PureTech completed a phase-2b trial of the drug back in December, and discussed the results with the US Food & Drug Administration. Celea plans to launch phase-3 testing by the end of the third quarter and is seeking external funding for the trial period, possibly through to commercialisation.
PureTech shares were down 1.2% at 128.00 pence on Tuesday afternoon in London, and have fallen 24% in the last 12 months.
By Holly Munks, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
PureTech